American Oriental Bioengineering Reports Second Quarter 2009 Financi...(SHAREHOLDERS' EQUITY Preferred stock ...)

Date:8/7/2009

SHAREHOLDERS' EQUITY Preferred stock, $0.001 par value; 2,000,000 shares authorized; 1,000,000 shares issued and outstanding at June 30, 2009 and December 31, 2008, respectively 1,000 1,000 Common stock, $0.001 par value; 150,000,000 shares authorized; 78,301,439 and 78,249,264 shares issued and outstanding at June 30, 2009 and December 31, 2008, respectively 78,301 78,249 Common stock to be issued 311,999 376,335 Prepaid forward repurchase contract (29,998,616) (29,998,616) Additional paid-in capital 196,752,860 195,741,544 Retained earnings (the restricted portion of retained earnings is $29,532,699 at June 30, 2009 and December 31, 2008, respectively) 171,019,548 149,923,681 Accumulated other comprehensive income 29,510,788 29,086,006 Total Shareholders' Equity 367,675,880 345,208,199 NON-CONTROLLING INTEREST 532,564 652,081 TOTAL EQUITY 368,208,444 345,860,280 TOTAL LIABILITIES AND EQUITY $540,796,581 $524,054,837 AMERICAN ORIENTAL BIOENGINEERING, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (UNAUDITED) THREE MONTHS ENDED SIX MONTHS ENDED JUNE 30, JUNE 30, 2009 2008 2009 2008 REVENUES $71,222,037 $59,010,005 $117,299,227 $97,778,603 COST OF GOODS SOLD 29,594,923 18,928,447 47,255,261 31,406,083 GROSS PROFIT 41,627,114 40,081,558 70,043,966 66,372,520 Selling and
'/>"/>

SOURCE American Oriental Bioengineering, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
3. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
4. American Oriental Bioengineering Announces Participation in September Investor Conferences
5. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
6. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
7. Tips from the Journals of the American Society for Microbiology
8. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
9. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
10. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
11. AUDIO from Medialink and Pfizer: Hispanic Heritage Month Reminds Us Increasing Numbers of Hispanic-Americans Do Not Have Health Insurance